Phase II trial demonstrates durable clinical benefit and survival in pretreated HER2-expressing solid tumors, supporting trastuzumab deruxtecan as a tumor-agnostic therapy.
Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.
No takes yet. Share an insight, caveat, or question.
Meric‐Bernstam et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: